Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
Citigroup Maintains Buy on Wave Life Sciences, Lowers Price Target to $15
Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London
Wave Life Sciences: Reversing Stock Losses Tricky Despite Near-Term AATD Readout
Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation - Slideshow
B. Riley Securities Reiterates Buy on Wave Life Sciences, Lowers Price Target to $18
WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program
Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript
Canaccord Genuity Maintains Buy on Wave Life Sciences, Raises Price Target to $44
Wave Life Sciences (WVE) Stock Rallies As Q3 Results Ease Loss Fears
Oppenheimer Maintains Outperform on Wave Life Sciences, Lowers Price Target to $29
Wave Life Sciences Ltd. Q3 2026 Earnings Call Summary
Wave Life Sciences (WVE) Q3 2026 Earnings Call Transcript
WAVE Life Sciences Q3 Earnings Call Highlights
Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript
Wave Life Sciences: Q3 Earnings Snapshot
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
WAVE Life Sciences Q3 EPS $(0.30) Beats $(0.33) Estimate, Sales $13.158M Beat $4.317M Estimate
WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.